3 results match your criteria: "Sungkyunkwan University School of Medicine (S.W.L)[Affiliation]"
Erratum to "COVID-19 Morbidity and Severity in Patients With Age-Related Macular Degeneration: A Korean Nationwide Cohort Study," American Journal of Ophthalmology, 239C, 159-169.
Am J Ophthalmol
December 2024
Department of Data Science, Sejong University College of Software Convergence (S.Y.M, S.W.L), Seoul, Republic of Korea; Department of Precision Medicine, Sungkyunkwan University School of Medicine (S.W.L), Suwon, Republic of Korea.
Real-World Incidence of Incident Noninfectious Uveitis in Patients Treated With BRAF Inhibitors: A Nationwide Clinical Cohort Study.
Am J Ophthalmol
November 2024
From the Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine (H.J., C.S.L., S.H.B., S.S.K., Y.J.K.), Seoul, Republic of Korea. Electronic address:
Article Synopsis
- The study investigates the incidence of noninfectious uveitis among skin melanoma and lung cancer patients receiving different treatments: BRAF inhibitors, immune checkpoint inhibitors (ICIs), or conventional chemotherapy.
- An analysis of over 77,000 patients showed that those on BRAF inhibitors had a significantly higher risk of uveitis (2.27%) compared to those on ICIs (0.35%) or chemotherapy (0.33%).
- The adjusted risk indicates that patients on BRAF inhibitors were over 7 times more likely to develop uveitis compared to those not treated with BRAF inhibitors, with even higher risks noted after matching for similar characteristics.
Uveitis Risk After the First Dose of COVID-19 Vaccination Based on Uveitis History: Matched Cohort and Crossover Case Series Study.
Am J Ophthalmol
June 2024
Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine (M.S.C., C.S.L., S.H.B., S.S.K., Y.J.K.), Seoul, Republic of Korea. Electronic address:
Purpose: To investigate the risk of noninfectious uveitis following the first dose of coronavirus disease 2019 (COVID-19) vaccination based on the uveitis history.
Design: Retrospective matched cohort and crossover case series study.
Methods: A random sample of 7 917 457 individuals who received COVID-19 vaccine between January 2021 and March 2022 in Korea, and had no recorded history of COVID-19 were categorized into the control and uveitis groups based on their uveitis history.